Mabwell Wins Wider China Indications for Denosumab Biosimilar as Global Push Accelerates

Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Mabwell (Shanghai) Bioscience Co., Ltd. Class H ( (HK:2493) ) has shared an update. Mabwell’s subsidiary Jiangsu T-mab BioPharma has secured approval from China’s National Medical Products Administration to expand the indications of its denosumab biosimilar Maiweijian injection to include bone metastases from solid tumors and multiple myeloma, for reducing skeletal-related events. The drug, already authorized in China for unresectable giant cell tumor of bone and positioned as a first-tier Xgeva biosimilar, now has a broader clinical scope that could enhance Mabwell’s competitiveness in oncology supportive care and increase its share in a fast-growing market segment. The company has validated Maiweijian’s similarity to the reference drug through head-to-head pharmacokinetic and efficacy trials published in leading journals, supporting its scientific and regulatory credentials. Internationally, Mabwell is accelerating commercialization in emerging markets, with regulatory approval in Pakistan, successful GMP inspection in Colombia’s INVIMA framework, and cooperation agreements covering 33 countries, moves that aim to tap into global demand reflected by robust Xgeva sales growth in China while cautioning investors about uncertainties in production and commercialization. More about Mabwell (Shanghai) Bioscience Co., Ltd. Class H Mabwell (Shanghai) Bioscience Co., Ltd. is a Chinese biopharmaceutical company focused on developing and commercializing biologic drugs, including biosimilars targeting oncology and bone-related diseases. Through its wholly owned subsidiary Jiangsu T-mab BioPharma, the company is building a presence in both the domestic Chinese market and emerging international markets for advanced injectable therapies. Average Trading Volume: 2,623,279 Current Market Cap: HK$15.37B